IMC (NASDAQ: IMCC) signs term sheet for 60% stake in quantum biodata firm up to $54M
October 23, 2025
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
IM Cannabis (NASDAQ: IMCC) announced on Oct 23, 2025 a non-binding term sheet to acquire a 60% equity interest in a quantum computing bio data company for up to $54 million.
Consideration may include cash, IMC shares and performance-linked earn-outs. The deal is subject to due diligence, definitive agreements, corporate and regulatory approvals, and customary closing conditions, and may not be completed as proposed. The move follows IMC’s exploration of additional business activities to enhance long-term growth and shareholder value.
IM Cannabis (NASDAQ: IMCC) ha annunciato il 23 ottobre 2025 una term sheet non impegnativa per acquisire una participazione azionaria del 60% di una società di dati bio su computazione quantistica per fino a 54 milioni di dollari.
La controparte può includere contanti, azioni IMC e earn-out legati alla performance. L’operazione è soggetta a due diligence, accordi definitivi, approvazioni societarie e regolamentari e condizioni di chiusura comuni, e potrebbe non essere realizzata come proposto. La mossa segue l’esplorazione da parte di IMC di ulteriori attività commerciali per migliorare la crescita a lungo termine e il valore per gli azionisti.
IM Cannabis (NASDAQ: IMCC) anunció el 23 de octubre de 2025 una hoja de términos no vinculante para adquirir una participación del 60% en el capital de una empresa de datos bio de computación cuántica por hasta 54 millones de dólares.
La contraprestación puede incluir efectivo, acciones de IMC y earn-outs vinculados al rendimiento. El acuerdo está sujeto a diligencia debida, acuerdos definitivos, aprobaciones corporativas y regulatorias y condiciones de cierre habituales, y podría no completarse tal como se propone. El movimiento sigue a la exploración por parte de IMC de actividades comerciales adicionales para potenciar el crecimiento a largo plazo y el valor para los accionistas.
IM Cannabis (NASDAQ: IMCC)은 2025년 10월 23일 비구속적 조건부 양해각서를 발표하여 양자 컴퓨팅 생체 데이터 회사의 60% 지분을 최대 5,400만 달러에 인수하는 것을 목표로 한다.
대가에는 현금, IMC 주식 및 성과 연계형 이행금(earn-outs)이 포함될 수 있다. 이 거래는 실사, 확정 계약, 기업 및 규제 승인, 관례적 종결 조건의 적용을 받으며, 제안대로 완료되지 않을 수 있다. 이번 조치는 IMC가 장기 성장과 주주 가치를 강화하기 위한 추가 사업 활동을 모색하고 있은 것을 따른다.
IM Cannabis (NASDAQ: IMCC) a annoncé le 23 octobre 2025 une lettre d’intention non engageante pour acquérir une participation de 60 % du capital d’une société de données bio d’informatique quantique pour jusqu’à 54 millions de dollars.
La contrepartie peut comprendre des espèces, des actions IMC et des earn-outs liés à la performance. L’opération est soumise à due diligence, accords définitifs, approbations d’entreprise et réglementaires, et conditions de clôture habituelles, et elle pourrait ne pas être réalisée telle quelle. Cette initiative s’inscrit dans l’exploration par IMC de activités commerciales additionnelles afin de renforcer la croissance à long terme et la valeur pour les actionnaires.
IM Cannabis (NASDAQ: IMCC) kündigte am 23. Oktober 2025 ein unverbindliches Term Sheet zum Erwerb einer 60%-igen Beteiligung an einem Unternehmen für Quantencomputing-Biodaten zu bis zu 54 Millionen Dollar an.
Die Gegenleistung kann Bargeld, IMC-Aktien und leistungsabhängige Earn-outs umfassen. Der Deal steht unter Vorbehalt von Due Diligence, endgültigen Vereinbarungen, unternehmens- und regulatorischen Genehmigungen sowie üblichen Abschlussbedingungen und könnte nicht wie vorgeschlagen abgeschlossen werden. Die Maßnahme folgt IMCs Erkundung zusätzlicher Geschäftstätigkeiten zur Stärkung des langfristigen Wachstums und des Aktionärswerts.
IM Cannabis (NASDAQ: IMCC) أعلنت في 23 أكتوبر 2025 عن ورقة شروط غير ملزمة للاستحواذ على 60% من حقوق الملكية في شركة بيانات حيوية حاسوبية كمّية مقابل حتى 54 مليون دولار.
قد تتضمن المقابلة نقداً، أسهم IMC ودفعات أرباح متعلقة بالأداء. الصفقة خاضعة للدراسة الواجبة، واتفاقيات حاسمة، وافقات شركة وتنظيمية، وشروط إغلاق معتادة، وقد لا تُستكمل كما هو مقترح. جاءت الخطوة في أعقاب استكشاف IMC لأنشطة تجارية إضافية لتعزيز النمو الطويل الأجل وقيمة المساهمين.
IM Cannabis (NASDAQ: IMCC) 于 2025年10月23日 公布了一份非约束性条款清单,拟以 60% 股权 收购一家量子计算生物数据公司,价格为 最多5400万美元。
对价可能包括现金、IMC股票以及以绩效为基础的业绩对价。交易需经尽职调查、达成正式协议、获得公司与监管部门批准,以及符合交易惯例的成交通条件,且不一定按原提案完成。此举是在 IMC 寻求扩大长期增长和提升股东价值的额外业务活动后的举动。
Positive
- 60% stake targeted in an advanced tech company
- Potential $54 million strategic investment
- Consideration includes cash, shares, and earn-outs
Negative
- Transaction is only a non-binding term sheet
- Deal completion conditioned on due diligence and approvals
- No assurance the transaction will close as proposed
Insights
Non-binding term sheet to buy 60% of a quantum bio‑data firm for up to $54 million; outcome uncertain and conditional.
IM Cannabis proposes to acquire a 60% stake in a company that applies quantum computing concepts to biological data, using a mix of cash, IMC shares and potential earn-outs for aggregate consideration up to $54 million. The structure described is preliminary: the agreement is a non‑binding term sheet and completion depends on due diligence, definitive agreements, required corporate and regulatory approvals, and customary closing conditions.
Key dependencies and risks include the non‑binding nature of the term sheet, milestone‑linked earn‑outs that tie value to future performance, and the need for regulatory and corporate approvals which could delay or prevent closing. The use of equity as part of the purchase consideration introduces shareholder dilution risk and links part of vendor compensation to IMC share performance.
Watch for three concrete next items: completion of due diligence and execution of definitive agreements, disclosure of the specific earn‑out milestones and metrics, and timing of required approvals (no dates provided). Expect material updates or definitive filings before any enforceable transfer occurs; treat the current announcement as exploratory through October 23, 2025.
TORONTO and GLIL YAM, Israel, Oct. 23, 2025 /PRNewswire/ — IM Cannabis Corp. (“IMC” or the “Company“) (NASDAQ: IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced the signing of a non-binding indicative term sheet for a proposed securities exchange agreement to acquire a 60% equity interest in a pioneering quantum computing bio data company (“The Target Company“) for aggregate consideration of up to $54 million.
The Target Company specializes in utilizing quantum computing principles to store, manipulate, and analyze BIO data more efficiently than current technologies, offering groundbreaking advancements in biological data processing and analytics.
Key Terms and Conditions
Under the terms of the term sheet, aggregate consideration of up to $54 million, would be payable in a combination of cash, IMC shares, and potential earn-out payments tied to agreed performance milestones.
The proposed transaction remains subject to the completion of due diligence, negotiation and execution of definitive agreements, receipt of all required corporate and regulatory approvals, and other customary closing conditions. There can be no assurance that any definitive agreement will be entered into or that the transaction will be completed on the terms described, or at all.
This term sheet follows the Company’s decision to explore the introduction of additional business activities, with the goal of enhancing long-term growth opportunities and creating further shareholder value.
No Offer or Solicitation
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its subsidiaries, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the Company advancing its strategy; the Company exploring additional business activities; the Company’s goal of enhancing long-term growth opportunities and creating further shareholder value; the Company and the Target Company’s ability to complete the proposed transaction; the expected terms of the proposed transaction, the number of securities of the Company that may be issued in connection with the proposed transaction; the ability of the Company and the Target Company to receive the requisite corporate and regulatory approvals having jurisdiction in connection with the proposed transaction; and the signing of a definitive agreement between the Company and the Target Company.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements for the proposed transaction; the failure of the Company and the Target Company to sign on a definitive agreement; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company and or the Target Company operates; risks associated with potential governmental and/or regulatory action with respect to the Company’s and/or the Target Company’s operations; the Company’s inability to complete the Proposed Transaction; the Company’s ability to continue to meet the listing requirements of the Nasdaq Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfill the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the multi front war Israel is facing; its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the Company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; the Company being unable to advance its strategy; the Company not exploring additional business activities; the Company being unable to meet its goal of enhancing long-term growth opportunities and/or creating further shareholder value; the Company being unable to amplify its commercial and/or brand power; and the Company failing to become a global high-quality cannabis player.
Readers are cautioned that the foregoing list is not exhaustive. Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 31, 2025, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made.
The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
a.taranko@imcannabis.de
Oren Shuster, CEO
IM Cannabis Corp.
info@imcannabis.com
Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/im-cannabis-signs-non-binding-term-sheet-to-acquire-60-stake-in-innovative-quantum-computing-bio-data-company-for-up-to-54-million-302592850.html
SOURCE IM Cannabis Corp.
FAQ
What did IM Cannabis (IMCC) announce on October 23, 2025?
IM Cannabis announced a non-binding term sheet to acquire a 60% equity interest in a quantum computing bio data company for up to $54 million.
How will IMCC pay for the proposed acquisition of the quantum bio data company?
Consideration would be paid in a combination of cash, IMC shares, and potential earn-out payments tied to performance milestones.
Is the IMCC acquisition of the quantum bio data company final?
No; the agreement is non-binding and the transaction is subject to due diligence, definitive agreements, and regulatory and corporate approvals.
What percentage of the target company would IM Cannabis own if the deal closes?
IM Cannabis would acquire a 60% equity interest in the target company.
What are the main deal conditions for IMCC’s proposed acquisition?
Completion depends on due diligence, negotiation of definitive agreements, required approvals, and other customary closing conditions.
What strategic rationale did IM Cannabis give for exploring this transaction?
IM Cannabis said the move follows its decision to explore additional business activities to enhance long-term growth and create further shareholder value.
Search
RECENT PRESS RELEASES
Related Post